Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis

Boyle A, Marra F, Peters E, et al. Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis. J Viral Hepat. 2020;27(4):371-375.

Publication Type:

Journal Article

Authors:

Boyle, A; Marra, F; Peters, E; et, al

Source:

J Viral Hepat, Volume 27, Issue 4, p.371-375 (2020)

Cited On:

Treatment-Naive Genotype 3 Without Cirrhosis

Export Citation:

RIS Format

Top